First, CCND1 amplification has been linked to resistance to the EGFR inhibitor gefitinib in experimental models of head & neck cancer [55], raising the possibility that it might also negatively impact the efficacy of potential anti-EGFR therapy in gastric cancer. This evidence concerns the gene CCND1 and head and neck cancer.